Update on mesalazine for inflammatory bowel disease

Research and Clinical Forums

Volumn 20, Issue 1, 1998, Pages 203-208

  Hanauer, S B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

CONFERENCE PAPER; CROHN DISEASE; DOSE RESPONSE; DRUG EFFICACY; ENTERITIS; HUMAN; ORAL DRUG ADMINISTRATION; RECTAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0031888661     PISSN: 01433083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. HANAUER, S.B. Drug Therapy: Inflammatory bowel disease. N. Engl. J. Med., 1996; 334(13): 841-848.
2. KORNBLUTH, A. and SACHAR, D.B. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol., 1997; 92(2): 204-211.
3. BRITISH SOCIETY OF GASTROENTEROLOCSY CLINICAL SERVICES & STANDARDS COMMITTEE. BSG Guidelines in Gastroenterology: Inflammatory Bowel Disease. September, 1996.
4. HANAUER, S.B. and MEYERS, S. Management of Crohn's disease in adults. Am. J. Gastroenterol., 1997; 92(2): 559-566.
5. MESSORI, A., BRIGNOLA, C., TRALLORI, G., RAMPAZZO, R., BARDAZZI, G., BELLOLI, C., D'ALBASIO, G., DE SIMONE, G. and MARTINI, N. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-anatysis. Am. J. Gastroenterol., 1994; 89(5): 692-698.
6. STEINHART, A.M., HEMPHILL, D. and GREENBERG, G.R. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am. J. Gastroenterol., 1994; 89(12): 2116-2124.
7. SUTHERLAND, L.R., MAY, G.R. and SHAFFER, E.A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann. Intern. Med., 1993; 118(7): 540-549.
8. BINDER, V. and DANISH 5-ASA STUDY GROUP. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig. Dis. Sci. 1987; 32(6): 598-602.
9. LÉMANN, I., GALIAN, A., RUTGEERTS, P., VAN HEUVERZWIJN, R., CORTOT, A., VITEAU, J.M., ELEWAUT, A., BELAICHE, J., FROGUEL, E. and MODIGLIANI, R. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment. Pharmacol. Ther., 1995; 9(5): 576-562.
10. HANAUER, S.B. et al. Dose ranging study of mesalamine enemas in the treatment of acute ulcerative proctosigmoidititis: results of a multicenter placebo-controlled trial. Inflamm. Bowel Dis.; in press.
11. CHRISTENSEN, L.A., FALLINGBORG, J., ABILDGAARD, K., JACOBSEN, B.A., SANCHEZ, G., HANSEN, S.H., BONDESEN, S., HVIDBERG, E.F. and RASMUSSEN, S.N. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment. Pharmacol. Ther., 1990; 4(5): 523-533.
12. RIJK, M.C., VAN SCHAIK, A. and VAN TONGEREN, J.H. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand. J. Gastroenterol., 1992; 27(10): 863-868.
13. HANAUER, S., SCHWARTZ, J., ROBINSON, M., ROUFAIL, W., ARORA, S., CELLO, J. and SAFDI, M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol., 1993; 88(8): 1188-1197.
14. MARTEAU, P. and CELLIER, C. Effets indesirables de 1' acide 5 aminosalicylique. Gastroenterol. Clin. Biol, 1997; 21(5): 377-386.
15. ROBINSON, M., HANAUER, S., HOOP, R., ZBROZEK, A. and WILKINSON, C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment. Pharmacol. Ther., 1994; 8(1): 27-34.
16. WALKER, A., SZNEKE, P., BIANCHI, A., FIELD, L., SUTHERLAND, L. and DREYER, N. 5-aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am. J. Gastroenterol, 1997; 92(5): 816-820.
17. MINER, P., HANAUER, S., ROBINSON, M., SCHWARTZ, J. and ARORA, S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig. Dis. Sci., 1995; 40(2): 296-304.
18. SINGLETON, J.W., HANAUER, S.B., GITNICK, G.L., PEPPERCORN, M.A., ROBINSON, M.G., GRUBLE, L.D. and KRAWITT, E.L. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology, 1993; 104(5): 1293-1301.
19. SINGLETON, J.W., HANAUER, S. and ROBINSON, M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig. Dis. Sci., 1995; 40(5): 931-935.
20. THOMSEN, O.O., CORTOT, A., JEWELL, D., WRIGHT, J.P., WINTER, T., VELOSO, F.T., VATN, M., PERSSON, T., NYLANDER, I. and THE INTERNATIONAL BUDESONIDE-MESALAZINE STUDY GROUP. Gastroenterology, (Suppl.), 1997; 112(4): A1104.
21. COLOMBEL, J.F., LEMANN, M., CASSAGNOU, M., BOUHNIK, Y., DUCLOS, B., DUPAS, J.L., NOTTEGHEM, B., MARY, J.Y. and THE GETAID, FRANCE. Controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Gastroenterology, (Suppl.), 1997; 112(4): A951.
22. GENDRE, J.P., MARY, J.Y., et al. Maintenance treatment of Crohn's disease using orallyadministered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders (French) Ann. Gastroenterol. Hepatol. (Paris), 1993; 29(5): 251-256.
23. HANAUER, S.B., KRAWITT, E.L., ROBINSON, M., RICK, G.G. and SAFDI, M.A. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Am. J. Gastroenterol., 1993; 88(9): 1343-1351.
24. MODIGLIANI, R., COLOMBEL, J.F., DUPAS, J.L., DAPOIGNY, M., COSTIL, V., VEYRAC, M., DUCLOS, B., SOULÉ, J.C., GENDRE, J.P., GALMICHE, J.P., DANNE, O., CADIOT, G., LAMOULIATTE, H., BELAICHE, J. and MARY, J.Y. Mesalamine in Crohn's disease with steroidinduced remission: effect on steroid withdrawal and remission maintenance. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology, 1996; 110(3): 688-693.
25. BRIGNOLA, C., COTTONE, M., PERA, A., ARDIZZONE, S., SCRIBANO, M.L., DE FRANCHIS, R., D'ARIENZO, A., D'ALBASIO, G. and PENNESTRI, D. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology, 1994; 108: 345-349.
26. CAPRILLI, R., ANDREOLI, A., CAPURSO, L., CORRAO, G., D'ALBASIO, G., GIOIENI, A., ASSUERO LANFRANCHI, G., PALADINI, I., PALLONE, F., PONTI, V. et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment. Pharmacol. Ther., 1994; 8: 35-43.